-
Orforglipron (CAS: 2212020-52-3)
API’s Name CAS No. US DMF EU DMF Patent Expiry Date(US) Orforglipron 2212020-52-3 Nov, 2026 Sep.26,2037 [Product] Provide the API as well as the SDD (Spray Dried Dispersion)
[Indication]
- Type 2 diabetes mellitus:To improve glycemic control in adults with type 2 diabetes mellitus.
- For clinical research, now it can be used for Chronic weight management in adults.
-
Osimertinib (CAS: 1421373-66-1)
API’s Name CAS No. US DMF EUDMF Patent Expiry Date( US) Osimertinib Mesylate 1421373-66-1 Nov,2026 Aug.8,2032 [Indication]
- For the adjuvant treatment of patients with non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R mutation.
- For the first-line treatment of adults with metastatic or locally advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation.
- For the treatment of adults with locally advanced or metastatic NSCLC who have disease progression after treatment with EGFR-TKI and whose tumors are positive for EGFR T790M mutation.
-
Oteseconazole (CAS: 1340593-59-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Oteseconazole Reduce the incidence rate ofrecurrent vulvovaginal candidiasis MycoviaPharmaceuticals Apr.22,2031 -
Obeticholic Acid
API’s Name Indication Specification US DMF EU DMF CEP Obeticholic Acid Biliary cholangitis In-House